Insights

Minaris Regenerative Medicine’s leaders and experts are proud to share their knowledge and insight with the cell and gene therapy industry. Please review our current and past blog posts on topics of interest to this emerging industry.

    *This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, formerly PCT or PCT Cell Therapy Services), apceth Biopharma GmBH are all now operations under the name Minaris Regenerative Medicine. Hitachi Chemical Co., Ltd. has been renamed Showa Denko Materials Co., Ltd.
    September 30, 2018

    5 Signs You Might Not Be Ready for a Cell Therapy Technology Transfer

    A technology transfer (“tech transfer”) for cell therapy manufacturing is the transfer of knowledge, experience, specifications, procedures, and data for manufacture of ...

    Read More
    September 27, 2018

    Why Would You Want to Perform a Technology Transfer

    In a recent article, we discussed some of the major telltale signs that your cell therapy product might not be ready for a technology transfer. To be successful, a cell ...

    Read More
    September 6, 2018

    Product Stewardship Throughout Your Cell Therapy Clinical Development

    Product stewardship is a vital part of any cell therapy technology transfer and/or clinical development. The basic definition of product stewardship is the technical ...

    Read More
    March 7, 2017

    Safety First: Shipping Cell Therapy Materials

    Cell therapies are at the forefront of saving lives – providing critical treatments to patients who might otherwise have very few viable options. Because these therapies ...

    Read More
    All Posts

    Subscribe to Our Email Distribution List
    © 2024 Minaris Regenerative Medicine   |  Privacy Policy   |  Imprint